Legal & General Group
ORIC icon

Legal & General Group’s Oric Pharmaceuticals ORIC Stock Holding History

Legal & General Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$372K Sell
29,336
-4,503
-13% -$51.1K ﹤0.01% 2438
2025
Q4 		$277K Buy
33,839
+713
+2% +$8.21K ﹤0.01% 2541
2025
Q3 		$398K Buy
33,126
+28,787
+663% +$303K ﹤0.01% 2506
2025
Q2 		$44K Sell
4,339
-28,119
-87% -$189K ﹤0.01% 2737
2025
Q1 		$181K Sell
32,458
-470
-1% -$4.11K ﹤0.01% 2624
2024
Q4 		$266K Hold
32,928
– – ﹤0.01% 2630
2024
Q3 		$338K Buy
32,928
+409
+1% +$4.04K ﹤0.01% 2580
2024
Q2 		$230K Buy
32,519
+29,266
+900% +$262K ﹤0.01% 2649
2024
Q1 		$44.7K Hold
3,253
– – ﹤0.01% 2791
2023
Q4 		$29.9K Hold
3,253
– – ﹤0.01% 2896
2023
Q3 		$19.7K Sell
3,253
-501
-13% -$4.11K ﹤0.01% 3039
2023
Q2 		$29.1K Buy
+3,754
New +$21.3K ﹤0.01% 2968
2022
Q3 		– Sell
-2,530
Closed -$11K – 3475
2022
Q2 		$11K Sell
2,530
-7,076
-74% -$28.2K ﹤0.01% 3365
2022
Q1 		$51K Hold
9,606
– – ﹤0.01% 2999
2021
Q4 		$142K Buy
9,606
+560
+6% +$8.73K ﹤0.01% 2829
2021
Q3 		$189K Buy
9,046
+4,889
+118% +$99.1K ﹤0.01% 2712
2021
Q2 		$74K Sell
4,157
-345
-8% -$7.56K ﹤0.01% 2826
2021
Q1 		$110K Buy
4,502
+1,260
+39% +$39.8K ﹤0.01% 2592
2020
Q4 		$110K Buy
3,242
+2,170
+202% +$62.3K ﹤0.01% 2562
2020
Q3 		$27K Sell
1,072
-340
-24% -$8.09K ﹤0.01% 2882
2020
Q2 		$47K Buy
+1,412
New +$45.1K ﹤0.01% 2747

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Legal & General Group's ORIC Position: Q1 2026 in Review

Legal & General Group reduced its Oric Pharmaceuticals (ORIC) stake by 13% in Q1 2026, selling an estimated $51.1K and leaving 29,336 shares worth $372K. The position accounts for ﹤0.01% of the portfolio, ranked #2438.

Legal & General Group first reported a position in ORIC in Q2 2020 and has held it in 21 quarters since. The position peaked at $398K in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Legal & General Group held 29,336 shares of Oric Pharmaceuticals worth $372K as of Q1 2026.
  • Legal & General Group sold 4,503 Oric Pharmaceuticals shares in Q1 2026, an estimated $51.1K.
  • Oric Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2438 holding.
  • Legal & General Group first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • Legal & General Group's Oric Pharmaceuticals position peaked at $398K in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.